Security
60 Degrees Pharmaceuticals, Inc. Common Stock · SXTP
SXTPNASDAQCommon stockCurrentCIK 1946563Updated Oct 28, 2026
SXTP price & chart
Loading TradingView…
NASDAQ:SXTP on TradingView ↗About the company
60 Degrees Pharmaceuticals, Inc., founded in 2010, develops and commercializes new medicines for the treatment and prevention of vector-borne disease. The Company won U.S. Food and Drug Administration approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018 and currently has 3 active clinical trials underway for babesiosis, an emerging tick-borne disease. ARAKODA is sold commercially in the U.S. and Australia. 60 Degrees also collaborates with prominent research and academic organizations in the U.S. and Australia to advance science around vector-borne disease. The Company is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com.
In the news
60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases ↗
Recent filings
Other Events
Items 8.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Other Events
Items 8.01
Regulation FD Disclosure
Items 7.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 6,689,344Source | 7,420,893Source | 4,282,694Source | 4,181,938Source | 4,327,251Source | 6,763,346Source | 5,977,867Source | 8,379,108Source | 5,366,211Source | 5,759,345Source | 7,783,771Source | 1,297,206Source |
| Property, Plant and Equipment, NetUSD | 227,752Source | 155,257Source | 242,714Source | 193,879Source | 159,591Source | 259,665Source | 155,792Source | 57,354Source | 246,365Source | 149,808Source | 57,761Source | 21,300Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 152,383Source | 264,351Source | 308,683Source | 143,704Source | 250,103Source | 243,212Source | 149,785Source | 217,417Source | 224,361Source | 157,084Source | 227,258Source | 164,255Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 4,115,779Source | 3,300,688Source | 1,022,606Source | 1,966,930Source | 1,576,602Source | 3,337,760Source | 3,451,500Source | — | 1,510,065Source | 1,659,353Source | — | — |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 674,036Source | 323,822Source | 567,040Source | 295,034Source | 296,370Source | 335,836Source | 488,243Source | 316,220Source | 509,644Source | 486,748Source | 231,332Source | 45,965Source |
| Inventory, NetUSD | 527,004Source | 452,036Source | 877,945Source | 799,421Source | 426,020Source | 910,603Source | 773,238Source | 435,377Source | 656,924Source | 442,764Source | 466,169Source | 518,578Source |
| Assets, CurrentUSD | 6,309,209Source | 6,890,991Source | 3,731,297Source | 3,844,355Source | 3,763,145Source | 6,260,469Source | 5,650,231Source | 7,905,808Source | 4,895,485Source | 5,386,277Source | 7,242,588Source | 1,099,004Source |
| Prepaid Expense and Other Assets, CurrentUSD | 992,390Source | 1,102,948Source | 1,263,706Source | 782,970Source | 1,458,293Source | 1,676,270Source | 937,250Source | 4,259,511Source | 978,131Source | 1,068,940Source | — | — |
| Operating Lease, Right-of-Use AssetUSD | — | — | — | — | — | — | — | — | — | — | 13,517Source | 12,647Source |
| Other Assets, NoncurrentUSD | 152,383Source | 374,645Source | 308,683Source | 143,704Source | 404,515Source | 243,212Source | 171,844Source | — | 224,361Source | 223,260Source | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 2,342,386Source | 1,458,046Source | 1,754,271Source | 1,836,234Source | 1,367,867Source | 2,018,867Source | 1,948,978Source | 1,253,630Source | 1,986,795Source | 1,804,339Source | 2,985,675Source | 25,446,266Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 9,567,439Source | 9,567,439Source | 9,567,439Source | 9,567,439Source | 9,858,040Source | 9,567,439Source | 9,567,439Source | 9,858,040Source | 9,567,439Source | 9,567,439Source | 9,858,040Source | — |
| Common Stock, Value, IssuedUSD | 410Source | 186Source | 264Source | 147Source | 102Source | 264Source | 147Source | 1,176Source | 116Source | 57Source | 581Source | 239Source |
| Additional Paid in CapitalUSD | 41,172,888Source | 34,815,642Source | 45,142,245Source | 36,856,091Source | 29,365,567Source | 45,095,267Source | 36,821,588Source | 29,359,498Source | 41,646,139Source | 34,860,590Source | 27,456,802Source | 5,164,461Source |
| Retained Earnings (Accumulated Deficit)USD | -46,454,556Source | -38,482,920Source | -52,246,855Source | -44,138,232Source | -36,323,135Source | -49,982,329Source | -42,404,506Source | -32,150,380Source | -47,893,115Source | -40,527,957Source | -32,580,850Source | -28,815,148Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 144,039Source | 139,207Source | 151,092Source | 142,809Source | 134,804Source | 148,540Source | 125,567Source | 131,667Source | 142,598Source | 135,471Source | 135,561Source | 73,708Source |
| Stockholders' Equity Attributable to ParentUSD | 4,430,220Source | 6,039,554Source | 2,614,185Source | 2,428,254Source | 3,035,378Source | 4,829,181Source | 4,110,235Source | 7,200,001Source | 3,463,177Source | 4,035,600Source | 4,870,134Source | -23,576,740Source |
| Liabilities and EquityUSD | 6,689,344Source | 7,420,893Source | 4,282,694Source | 4,181,938Source | 4,327,251Source | 6,763,346Source | 5,977,867Source | 8,379,108Source | 5,366,211Source | 5,759,345Source | 7,783,771Source | 1,297,206Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 2,197,394Source | 1,310,151Source | 1,605,095Source | 1,690,757Source | 1,219,197Source | 1,875,670Source | 1,802,476Source | 1,104,170Source | 1,842,792Source | 1,657,220Source | 2,835,424Source | 23,921,211Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | — | — | — | — | 529,449Source | — | — | 13,650Source | 13,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | -83,262Source | -76,707Source | -85,762Source | -82,550Source | -75,994Source | -84,702Source | -81,346Source | -74,523Source | -83,761Source | -80,594Source | -72,038Source | -572,320Source |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 4,115,779Source | — | 1,022,606Source | 1,966,930Source | — | 3,337,760Source | 3,451,500Source | — | 2,750,786Source | 3,387,825Source | — | — |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 0Source | — | 698,732Source | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 150,000Source | 150,000Source | 150,030Source | 150,000Source | 150,000Source | 150,030Source | 150,000Source | 150,000Source | 144,003Source | 150,000Source | 150,000Source | — |
| Long-term Debt, Current MaturitiesUSD | 8,772Source | 8,772Source | 2,003Source | 8,772Source | 8,772Source | 8,772Source | 8,772Source | 8,772Source | 8,772Source | 8,772Source | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | — | — | — | — | — | — | 144,003Source | — | — | — |
| Short-term InvestmentsUSD | 0Source | 1,711,497Source | — | 0Source | — | — | — | — | 1,240,721Source | 1,728,472Source | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -2,317,036Source | -2,160,498Source | -2,265,586Source | -1,734,930Source | -2,090,155Source | -1,877,301Source | -7,368,325Source | -7,955,663Source | -3,813,800Source | -6,177,784Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | 12,225Source | 4,334Source | 16,950Source | 9,236Source | 16,700Source | 6,694Source | 43,324Source | 11,726Source | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 212,605Source | — |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -173,808Source | 1,495Source | 22,896Source | 255,416Source | 185,367Source | -100,397Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 2,002Source | 330,474Source | 465,837Source | -23,405Source | -212,747Source | -10,126Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -2,741,559Source | -1,597,366Source | -6,849,022Source | -5,648,088Source | -4,542,910Source | -1,009,980Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 1,193,560Source | 1,702,518Source | 254,916Source | -1,889,114Source | -115,888Source | -60,133Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 30,000Source | 2,678Source | 139,881Source | 103,773Source | 57,623Source | — |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | 18,000Source | 18,000Source | — | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 3,369,752Source | 1,696,899Source | 6,437,691Source | 7,053,571Source | 6,474,565Source | 1,221,706Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 1,827,695Source | 1,792,147Source | -149,288Source | -483,132Source | 1,877,620Source | 149,466Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 4,115,779Source | 3,300,688Source | 1,022,606Source | 1,966,930Source | 3,337,760Source | 3,451,500Source | 1,510,065Source | 1,659,353Source | 2,142,485Source | 264,865Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 8,772Source | 8,772Source | 179,117Source | 2,193Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | 2,000Source | 1,000Source | 1,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | 5,942Source | -9,904Source | 7,127Source | 499Source | — | — |
| Additional Financial Items | ||||||||||||
| AmortizationUSD | — | — | — | — | — | — | 9,165Source | 10,103Source | 39,548Source | 38,502Source | 29,157Source | 5,118Source |
| Share-based Payment Arrangement, ExpenseUSD | — | — | 79,000Source | 668,974Source | 98,405Source | 78,620Source | 124,102Source | 186,763Source | 456,344Source | 3,608,648Source | 119,246Source | 0Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | 0Source | — | — | 151,969Source | 155,274Source | — | 0Source | 52,628Source | 4,955Source |
| Amortization of Intangible AssetsUSD | — | — | 10,605Source | 10,325Source | 13,860Source | 10,442Source | 9,165Source | 10,103Source | 39,548Source | 38,502Source | 29,157Source | 5,118Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 4,115,779Source | — | 1,022,606Source | 1,966,930Source | 3,337,760Source | 3,451,500Source | 2,750,786Source | 3,387,825Source | — | — |
| DepreciationUSD | — | — | — | — | — | — | 16,700Source | 6,694Source | 43,324Source | 11,726Source | 21,162Source | 27,648Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | — | — | — | — | -4,567Source | 5,105Source | 266,089Source | 1,665,966Source | — | — |
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | — | — | — | — | — | — | — | — | — | — | 5,379,269Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | — | — | -61,853Source | 2,127Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | — | — | — | — | — | — | 266,089Source | — | — | — |
| Gain (Loss) on Sale of DerivativesUSD | — | — | — | -56,712Source | — | — | — | — | — | — | -37,278Source | -10,312Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | — | -1,231,480Source | 120,683Source |
| General and Administrative ExpenseUSD | — | — | 1,506,620Source | 1,215,053Source | 1,729,247Source | 1,632,236Source | 1,889,874Source | 1,723,136Source | 6,279,823Source | 5,024,985Source | 4,241,836Source | 1,303,722Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | — | — | — | — | — | -220,977Source | 78,840Source |
| Income Tax Expense (Benefit)USD | — | — | 250Source | 250Source | — | 1,500Source | — | 63Source | 0Source | 250Source | 250Source | 500Source |
| InterestExpenseNonoperatingUSD | — | — | 1,708Source | 1,467Source | 1,403Source | 1,221Source | 1,389Source | 1,790Source | 7,805Source | 7,912Source | — | — |
| Inventory Write-downUSD | — | — | 436,561Source | 1,165Source | 27,842Source | 0Source | 3,496Source | 35Source | 445,181Source | 22,046Source | 191,111Source | 162,222Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,316,324Source | -2,159,785Source | -2,264,526Source | -1,733,726Source | -2,089,214Source | -1,876,549Source | -7,365,158Source | -7,947,107Source | -3,765,702Source | -6,181,720Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -712Source | -713Source | -1,060Source | -1,204Source | -941Source | -752Source | -3,167Source | -8,556Source | -48,098Source | 3,936Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -2,443,191Source | -2,271,953Source | -2,396,281Source | -1,843,189Source | -2,208,584Source | -2,004,611Source | -7,859,087Source | -8,430,498Source | -3,924,563Source | -6,183,847Source |
| Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | 390,254Source | — | — | — |
| Operating ExpensesUSD | — | — | 2,316,397Source | 2,155,116Source | 2,327,900Source | 1,864,148Source | 2,171,338Source | 2,093,949Source | 8,385,979Source | 10,011,511Source | 4,933,606Source | 1,829,285Source |
| Other Nonoperating Income (Expense)USD | — | — | 31,550Source | 16,623Source | 12,584Source | 13,066Source | 10,762Source | 30,322Source | 131,970Source | 101,464Source | -83,116Source | -43,238Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 1,047,692Source | 1,047,692Source |
| Gain (Loss) on Disposition of Other Assets | — | — | — | — | — | — | — | — | — | — | — | — |
| Impairment of Intangible Assets (Excluding Goodwill) | — | — | —Source | —Source | — | —Source | — | — | — | — | — | — |
| Other Operating Income (Expense), Net | — | — | — | —Source | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 437,602Source | 135,293Source | 207,898Source | 100,932Source | 162,092Source | 163,552Source | 1,005,471Source | 607,574Source | 253,573Source | 223,208Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Operating Income (Loss)USD | — | — | -2,325,525Source | -2,118,692Source | -2,271,102Source | -1,606,328Source | -2,094,961Source | -1,910,938Source | -7,758,579Source | -9,714,931Source | -5,154,583Source | -1,750,445Source |
| Other Nonoperating Income (Expense)USD | — | — | 31,550Source | 16,623Source | 12,584Source | 13,066Source | 10,762Source | 30,322Source | 131,970Source | 101,464Source | -83,116Source | -43,238Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -2,316,786Source | -2,160,248Source | -2,265,586Source | -1,734,930Source | -2,090,155Source | -1,877,301Source | -7,368,325Source | -7,955,413Source | -3,813,550Source | -6,177,284Source |
| Income Tax Expense (Benefit)USD | — | — | 250Source | 250Source | — | 1,500Source | — | 63Source | 0Source | 250Source | 250Source | 500Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -712Source | -713Source | -1,060Source | -1,204Source | -941Source | -752Source | -3,167Source | -8,556Source | -48,098Source | 3,936Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,316,324Source | -2,159,785Source | -2,264,526Source | -1,733,726Source | -2,089,214Source | -1,876,549Source | -7,365,158Source | -7,947,107Source | -3,765,702Source | -6,181,720Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.66Source | -4.65Source | -0.9Source | -5.01Source | -1.28Source | -6.25Source | -11.73Source | -18.55Source | -0.99Source | -2.61Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.66Source | -2.92Source | -0.9Source | -5.01Source | -1.28Source | -6.25Source | -11.73Source | -18.55Source | -0.99Source | -2.61Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 3,675,407Source | 488,654Source | 2,653,848Source | 368,250Source | 1,725,758Source | 320,890Source | 670,211Source | 454,582Source | 3,960,280Source | 2,367,729Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 3,675,407Source | 2,152,682Source | 2,653,848Source | 368,250Source | 1,725,758Source | 320,890Source | 670,211Source | 454,582Source | 3,960,280Source | 2,367,729Source |
| Interest Expense (non-operating)USD | — | — | 1,708Source | 1,467Source | 1,403Source | 1,221Source | 1,389Source | 1,790Source | 7,805Source | 7,912Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 10,605Source | 10,325Source | 13,860Source | 10,442Source | 9,165Source | 10,103Source | 39,548Source | 38,502Source | 29,157Source | 5,118Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 250Source | 250Source | 500Source |
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | — | — | — | — | — | — | — | — | — | — | 5,379,269Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | — | — | -61,853Source | 2,127Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | — | — | — | — | — | — | 266,089Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 1,506,620Source | 1,215,053Source | 1,729,247Source | 1,632,236Source | 1,889,874Source | 1,723,136Source | 6,279,823Source | 5,024,985Source | 4,241,836Source | 1,303,722Source |
| Gross ProfitUSD | — | — | -100,088Source | 23,606Source | 56,798Source | 50,881Source | 76,377Source | 90,280Source | 223,776Source | 222,809Source | -220,977Source | -209,162Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | — | — | — | — | — | -220,977Source | 78,840Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -6,908,764Source | -7,372,032Source | -3,006,861Source | -5,807,367Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 2,286,637Source | 3,989,359Source |
| Interest Expense, DebtUSD | — | — | — | 0Source | — | — | — | — | — | 0Source | 66,558Source | 115,546Source |
| Interest Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | 1,341,033Source | -4,426,839Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 8,739Source | -41,556Source | 5,516Source | -128,602Source | 4,806Source | 33,637Source | — | 1,759,518Source | — | — |
| Management Fee ExpenseUSD | — | — | — | — | — | — | — | — | — | 30,000Source | 30,000Source | — |
| Net Income (Loss) Attributable to Nonredeemable Noncontrolling InterestUSD | — | — | — | -713Source | — | — | — | — | — | — | -48,098Source | 3,936Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -2,443,191Source | -2,271,953Source | -2,396,281Source | -1,843,189Source | -2,208,584Source | -2,004,611Source | -7,859,087Source | -8,430,498Source | -3,924,563Source | -6,183,847Source |
| Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | 390,254Source | — | — | — |
| Operating ExpensesUSD | — | — | 2,316,397Source | 2,155,116Source | 2,327,900Source | 1,864,148Source | 2,171,338Source | 2,093,949Source | 8,385,979Source | 10,011,511Source | 4,933,606Source | 1,829,285Source |
| Other General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | — | 163,228Source | 1,543,803Source | — |
| Preferred Stock Dividends and Other AdjustmentsUSD | — | — | 128,097Source | 116,571Source | 134,307Source | 126,705Source | 125,312Source | 118,158Source | 501,056Source | 483,301Source | 220,714Source | — |
| Research and Development ExpenseUSD | — | — | 809,777Source | 940,063Source | 598,653Source | 231,912Source | 281,464Source | 370,813Source | 2,106,156Source | 4,986,526Source | 691,770Source | 525,563Source |
| Revenue Not from Contract with Customer, OtherUSD | — | — | 90,960Source | 12,818Source | — | 206,939Source | — | 92,731Source | 403,624Source | 73,771Source | — | 288,002Source |
| Other Operating Income (Expense), Net | — | — | — | —Source | — | — | — | — | — | — | — | — |
Offerings
Registration 333-298349
Filing attachments
ea030969001ex99-1.htm · 8-K · 2026-10-27
Exhibit 99.1 60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients All five completed patients (100%) reported much or very much improved clinical outcomes and tested negative for Babesia on conventional PCR tests Four of five completed patients (80%) were negative on highly sensitive post-treatment NAT testing Results reinforce favorable retreatment-free outcomes reported with tafenoquine–a…
Read attachment ↗ea030933901ex99-1.htm · 8-K · 2026-10-23
Exhibit 99.1 Tafenoquine for Babesiosis Progress across acute, relapsing and chronic disease Geoffrey S. Dow, PhD Chief Executive Officer 2026 ILADS Annual Scientific Conference October 22 - 25, 2026 | Herndon, Virginia Reframing Complex Disease: Pathways to Treatment 2026 update A marketed antimalarial platform now has converging evidence across three clinical settings. CHRONIC DIAGNOSTICS RELAPSING DISEASE HOSPITAL READOUT Regulatory objective A potential sNDA in 2027 - and a request for nati…
Read attachment ↗ea030776101ex99-1.htm · 8-K · 2026-10-06
Exhibit 99.1 Tafenoquine for Severe Babesiosis Study Interim Data Readout Webinar October 6, 2026 Today's discussion • Clinical context and current standard of care • Published evidence supporting tafenoquine + atovaquone • Hospital study interim analysis and DSMB feedback • Next steps and regulatory path • Near term catalysts 1 Disclaimer and Forward-Looking Statements DISCLAIMER. The information contained herein has been prepared to assist prospective investors in making their own evaluation…
Read attachment ↗ea030776101ex99-2.htm · 8-K · 2026-10-06
Exhibit 99.2 60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA After a scheduled interim analysis of the severe babesiosis study on October 1, 2026, the DSMB recommended completing the study with the originally planned number of patients (N=33); the study remains blinded ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── As of the s…
Read attachment ↗ea030486201ex99-1.htm · 8-K · 2026-09-08
EX-99.1 2 ea030486201ex99-1.htm 60 DEGREES PHARMACEUTICALS, INC. INVESTOR PRESENTATION, DATED SEPTEMBER 8, 2026 Exhibit 99.1 H.C. Wainwright Presentation 60 Degrees Pharmaceuticals, Inc. September 2026 Targeted therapies for vector-borne disease Investment focus A marketed antimalarial platform creates a path to potential indication expansion in babesiosis Commercial base ARAKODA® malaria prophylaxis Clinical vector Babesiosis development program Regulatory arc sNDA strategy + milestones ©2…
Read attachment ↗ea030026001ex99-1.htm · 8-K · 2026-08-04
EX-99.1 7 ea030026001ex99-1.htm PRESS RELEASE DATED JULY 30, 2026 Exhibit 99.1 60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules WASHINGTON, July 30, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP, SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced that it has entered into definitive agreements for the issuance an…
Read attachment ↗